- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940660
Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality Disorder (GPMDBT)
Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality Disorder: a Randomized Controlled Trial
The present non-inferiority randomized controlled trial aims at comparing the efficacy of 6-month Good Psychiatric Management to 6-month Dialectical-Behavior Therapy for personality disorder (and borderline personality disorder). In addition, six mechanisms of change are systematically tested within a within- and between-person design. In-session physiology assesses the emotional engagement and non-verbal synchrony, while out-of-session self-report questionnaires (i.e., diary) assess generalized skills and capabilities.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ueli Kramer, PhD
- Phone Number: 0213140050
- Email: ueli.kramer@chuv.ch
Study Locations
-
-
Canton of Vaud
-
Lausanne, Canton of Vaud, Switzerland, 1004
- Recruiting
- Lausanne University Hospital
-
Contact:
- Ueli Kramer, PhD
- Phone Number: 0213140050
- Email: ueli.kramer@chuv.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Borderline Personality Disorder; Moderate Personality Disorder
Exclusion Criteria:
- neurological disorder; schizophrenia; self-reported cardiological diagnosis; self-reported pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 6 month Good Psychiatric Management
|
Use of interpersonal hypersensitivity model |
|
Active Comparator: 6 month Dialectical Behavior Therapy
|
use of chain analyses and emotion regulation strategies according to protocol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ZAN-BPD
Time Frame: 6 months
|
Zanarini Borderline Personality Disorder Scale (Zanarini, 2003) ranges between 0 and 36, higher scores mean more symptom load (so worse outcome). |
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026-00651
- SNSF (Other Grant/Funding Number: Swiss National Science Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.